CONDITION
Histiocytic Sarcoma in Bernese Mountain Dogs
Histiocytic sarcoma is a cancer that arises from a type of immune cell called a histiocyte. These cells normally move through tissues as part of the body's surveillance system, but in this condition they begin to multiply without the usual constraints. In Bernese Mountain Dogs, this cancer occurs more commonly than in most other breeds, reflecting an inherited susceptibility that researchers continue to study. Owners often first notice signs that can seem vague or unconnected—reduced appetite, weight loss, lethargy, difficulty breathing, limping, or swelling in a limb or under the skin. Because the disease can start in different parts of the body—lung, spleen, bone, lymph nodes, skin, or brain—the early picture varies. The course tends to be measured in weeks to months rather than years, and signs often prompt investigation relatively quickly once they appear. This page explores what signs may be observed and when they tend to develop, what is happening in the body at a cellular level, how the condition is investigated through imaging and laboratory tests, and what treatment and supportive approaches exist. The goal is to help you understand the nature of the condition and the shape of the decisions that may follow.
Why this matters now
Histiocytic sarcoma in Bernese Mountain Dogs tends to appear in middle-aged to older adults, most commonly between six and nine years of age, though younger dogs can occasionally be affected. The breed carries an inherited susceptibility that appears to be polygenic, meaning multiple genes contribute to the risk rather than a single mutation. Males and females appear to be affected in roughly equal numbers, and there is no clear link to environmental exposures or nutrition.
Once the cancer begins, it typically progresses over weeks to a few months rather than years. The speed can vary depending on where the disease starts and how widely it has spread by the time signs first appear. Some dogs show signs that prompt investigation within days, while others may have subtle changes that become clearer over several weeks. The pattern is often one of gradual decline punctuated by more obvious shifts—an appetite that dwindles further, breathing that becomes more laboured, or a limp that no longer resolves with rest.
Signals & patterns
Early signals
Reduced appetite or weight loss
An owner may notice the dog shows less interest in meals, leaves food in the bowl, or begins to lose condition despite no obvious change in routine. This can reflect the metabolic effects of cancer or discomfort in an affected organ.
Lethargy or reduced stamina
The dog may seem less willing to engage in walks, tire more quickly, or spend more time resting. This pattern can be subtle at first and may be attributed to ageing or weather, but it tends to become more consistent over days to weeks.
Coughing or faster breathing
If the lungs are involved, the dog may develop a cough that does not resolve, or the owner may notice the breathing rate is higher than usual, even at rest. This reflects space-occupying masses or fluid accumulation in the chest.
Limping or reluctance to bear weight
When bone is affected, the dog may begin to favour one leg, show stiffness, or resist jumping or climbing stairs. The limp often persists and may worsen, unlike the intermittent pattern of a soft-tissue strain.
Swelling under the skin or in a limb
A firm, growing lump may appear on a leg, along the body wall, or over a joint. The swelling can be painless initially but tends to enlarge steadily over a period of weeks.
Later signals
Difficulty breathing or open-mouth breathing
As disease in the chest progresses, the dog may struggle to take in enough air, breathe with the mouth open, or adopt a posture with the elbows turned outward to expand the chest. This reflects worsening lung involvement or fluid accumulation.
Collapse or sudden weakness
If the spleen is severely affected and ruptures, the dog may collapse suddenly due to internal bleeding. This can present as pale gums, rapid heart rate, and profound weakness, and the episode may be preceded by more subtle signs of abdominal discomfort.
Neurological changes
When the brain is involved, the owner may observe seizures, head tilt, circling, changes in behaviour, or difficulty coordinating movement. These signs reflect pressure from growing masses within the skull.
Severe lameness or fracture
In cases where bone is extensively weakened by tumour, the limb may fracture with minimal trauma, or the dog may become unable to bear any weight. This represents advanced local disease.
Click to read about the biological mechanisms
How this is usually investigated
Investigation typically begins with a clinical examination and a detailed history of when signs first appeared and how they have changed. Because the condition can affect multiple organs and present in varied ways, imaging is usually the next step, helping to locate masses and assess how widely the disease has spread. Laboratory tests provide information about organ function and the inflammatory response, and a tissue sample is often needed to confirm the diagnosis and distinguish this cancer from other conditions that can look similar.
Thoracic and abdominal imaging
Fine-needle aspiration or biopsy
Blood tests
Bone imaging
Immunohistochemistry
Options & trade-offs
Management is usually tailored to the individual animal and the extent of disease at the time of diagnosis. Some approaches aim to reduce tumour burden or slow progression, while others focus on maintaining comfort and quality of life. Different combinations suit different households, depending on the dog's age, overall health, the owner's circumstances, and how the disease is behaving.
Surgery
If the disease appears confined to a single site—such as a mass in the spleen, a lymph node, or a limb bone—surgical removal may be considered. The goal is to remove the primary tumour, which can improve comfort and sometimes extend the period before signs return. In the case of a splenic mass, splenectomy can resolve anaemia and abdominal discomfort. For bone lesions, amputation may be an option if the tumour has not spread widely.
Trade-offs: Surgery carries the usual risks of anaesthesia and recovery, and there is often microscopic disease present elsewhere even when imaging shows a single mass. Recurrence or progression at other sites is common, and the time gained varies considerably between individuals.
Chemotherapy
Systemic chemotherapy can be used after surgery or on its own when surgery is not feasible. Protocols typically involve drugs such as lomustine or doxorubicin, given at intervals over several weeks to months. The aim is to slow tumour growth and delay progression, though complete remission is uncommon.
Trade-offs: Chemotherapy requires repeated veterinary visits and monitoring of blood counts, and it can cause side effects such as gastrointestinal upset, bone marrow suppression, or liver changes. Response rates vary, and the disease often progresses despite treatment.
Radiotherapy
Radiation can be directed at a specific tumour site, such as a bone lesion or a mass in the brain, to reduce pain and slow local progression. It is sometimes used after incomplete surgical removal or when surgery is not an option. Treatment is usually delivered over several sessions at a specialist centre.
Trade-offs: Access is limited to referral centres, and the logistics of repeated visits can be challenging. Radiotherapy is most useful for localised disease and does not address spread to other organs. Side effects depend on the site being treated and can include skin irritation or effects on nearby tissues.
Supportive care
Pain relief, anti-inflammatory medications, and appetite support can help maintain comfort and quality of life, whether used alongside other treatments or on their own. This may include drugs such as nonsteroidal anti-inflammatories, opioids, or appetite stimulants, adjusted as the dog's condition changes. Monitoring for signs of discomfort or declining function allows adjustments to be made over time.
Trade-offs: Supportive care does not alter the course of the disease but can make a meaningful difference to day-to-day experience. Some medications carry risks—NSAIDs can affect the kidneys or stomach, opioids can cause sedation—and careful observation is needed to balance benefit and side effects.
Observation with deferred intervention
In cases where the diagnosis is uncertain or the dog appears comfortable despite imaging findings, some owners choose to monitor closely and introduce treatment only if specific signs develop. This approach can be workable when the dog is eating well, mobile, and showing no distress, and when the owner is prepared to reassess frequently.
Trade-offs: The disease can progress quickly, and waiting may mean that treatment options become less effective or that the window for intervention narrows. This approach suits situations where the dog's quality of life is currently good and the owner is comfortable with uncertainty.
Common misconceptions
"If the tumour is removed surgically, the cancer is cured."
Histiocytic sarcoma tends to have spread at a microscopic level even when imaging shows a single mass. Surgery can improve comfort and delay progression, but recurrence or the appearance of new tumours at other sites is common. The time gained varies widely between individuals.
"Chemotherapy in dogs causes the same severe side effects as it does in people."
Chemotherapy protocols for dogs are generally designed to minimise side effects, and most dogs tolerate treatment without severe illness. Mild gastrointestinal upset or temporary changes in blood counts can occur, but serious toxicity is less common. The goal is often to extend good-quality time rather than to pursue remission at any cost.
"A normal blood test rules out cancer."
Many dogs with histiocytic sarcoma have normal or only mildly abnormal blood results, particularly early in the disease. Blood tests provide useful background information but cannot confirm or exclude the diagnosis. Imaging and tissue sampling are usually needed to establish what is happening.
Related conditions
Multicentric Lymphoma in Dogs
Multicentric lymphoma is another cancer arising from immune cells, and like histiocytic sarcoma, it can present with vague systemic signs such as lethargy, weight loss, and swelling in multiple locations. The two conditions differ in their cell of origin and progression patterns, but both may prompt investigation when owners notice unexplained lumps or declining condition.
Hemangiosarcoma
Haemangiosarcoma shares with histiocytic sarcoma a tendency to develop in organs such as the spleen and to progress rapidly over weeks to months. Both cancers can cause sudden weakness, difficulty breathing, or internal bleeding, and they may be considered alongside one another when imaging reveals masses in the chest or abdomen.
Osteosarcoma in Dogs
Osteosarcoma and histiocytic sarcoma can both present with limping or swelling in a limb, though osteosarcoma arises from bone tissue while histiocytic sarcoma may involve bone or soft tissue. In either case, imaging and biopsy are used to distinguish between these and other causes of lameness in middle-aged to older dogs.
Brain Tumours
Histiocytic sarcoma can occasionally develop in or spread to the brain, producing neurological signs such as seizures, altered behaviour, or difficulty walking. When these signs appear, brain tumours of various types—including histiocytic sarcoma—may be considered during the diagnostic process.
Splenic Mass
A splenic mass discovered on imaging or during investigation of collapse or abdominal swelling may represent histiocytic sarcoma, haemangiosarcoma, or other growths. The nature of the mass is typically clarified through biopsy or examination of the tissue after surgical removal.
If you are navigating a diagnosis or weighing different approaches, it can be useful to understand how other conditions that affect longevity and healthspan in Bernese Mountain Dogs—such as lymphoma or mast cell disease—compare in their patterns and trajectories. The broader context of immune-mediated and cancer-related conditions in the breed may help frame conversations about monitoring, intervention timing, and what to watch for as circumstances change. Other pages in this pillar explore those themes in more detail.